Skip to main content
PharmaTher Holdings Ltd. logo

PharmaTher Holdings Ltd. — Investor Relations & Filings

Ticker · PHRM ISIN · CA71716H1082 LEI · 529900PIPSZ1ZSWF3A21 CSE Manufacturing
Filings indexed 279 across all filing types
Latest filing 2021-04-30 Regulatory Filings
Country CA Canada
Listing CSE PHRM

About PharmaTher Holdings Ltd.

https://www.pharmather.com/

PharmaTher Holdings Ltd. is a specialty pharmaceutical company dedicated to the research, development, and commercialization of novel therapeutics, primarily focusing on ketamine and psychedelic compounds. The company's strategy involves advancing three core assets: the KETARX™ portfolio of ketamine drugs, which targets neuropsychiatric and pain disorders; the proprietary PharmaPatch™ microneedle patch platform, designed for the transdermal delivery of ketamine, psychedelics, and GLP-1 drugs; and a 49% ownership interest in Sairiyo Therapeutics Inc., which is developing a patented oral formulation of cepharanthine for infectious diseases and cancer. PharmaTher is focused on achieving regulatory approval for its pipeline candidates to address significant global unmet medical needs in mental health, neurological, and pain disorders.

Recent filings

Filing Released Lang Actions
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings
2021-04-30 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings
2021-04-30 English
Interim MD&A - English.pdf
Regulatory Filings
2021-04-30 English
Interim financial statements/report – English.pdf
Regulatory Filings
2021-04-30 English
News release - English.pdf
Regulatory Filings
2021-04-27 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing the submission of an Investigational New Drug (IND) application to the FDA for a Phase 2 clinical trial. It discusses the clinical trial design, the drug being tested (ketamine), and the potential future steps if the trial is successful. There are no financial statements, earnings data, or regulatory filings related to financial performance. The content is focused on clinical trial and drug development progress, which is typical of a Capital/Financing Update or a Regulatory Filing. However, since this is an announcement of a regulatory submission and clinical trial initiation rather than a financing event or a detailed regulatory compliance document, it best fits under Regulatory Filings (RNS) as a general regulatory announcement. The document length is 8130 characters, which is substantial but the content is clearly an announcement rather than a full report or financial document.
2021-04-20 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.